These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7843823)

  • 1. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.
    Schito GC; Georgopoulos A; Prieto J
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():7-11. PubMed ID: 12077154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
    Bauernfeind A
    Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens.
    Speciale A; Caccamo F; Blandino G; Giacchi GT; Aleo G; Nicoletti G
    Chemotherapy; 1996; 42(1):1-10. PubMed ID: 8751262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Bryson HM; Brogden RN
    Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases.
    Cullmann W; Dick W
    Zentralbl Bakteriol; 1990 Sep; 273(4):501-17. PubMed ID: 2248685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W; Dick W; Stieglitz M; Opferkuch W
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.